Aclaris Therapeutics Added to the NASDAQ Biotechnology Index (NBI)

Core Viewpoint - Aclaris Therapeutics, Inc. has been added to the Nasdaq Biotechnology Index, effective December 19, 2025, indicating recognition of its market position and potential in the biopharmaceutical sector [1]. Group 1: Company Overview - Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases [4]. - The company has a multi-stage portfolio of product candidates supported by a robust research and development engine [4]. Group 2: Nasdaq Biotechnology Index - The Nasdaq Biotechnology Index (NBI) tracks the performance of securities classified as biotechnology or pharmaceutical, requiring companies to meet specific eligibility criteria such as minimum market capitalization and average daily trading volume [2]. - The NBI is evaluated annually in December and uses a modified capitalization-weighted methodology for its calculations [2].